Clinical applications of oXiris membranes: Targeting inflammation and renal dysfunction in ICU patients.

J Intensive Med · 2026 · PMC13323533 · PMID 42396239

Europe PMC DOI

hedged sentence

0.1170

closest p · 2.3× alpha

0.1170

boldest claim

The sentences

did not reach statistical significanceP =0.117not close (p > 0.1)

[ 45 ] including 58 COVID-19 patients requiring CRRT, oXiris significantly reduced IL-6 levels at 24 and 72 h and improved partial pressure of arterial oxygen/fraction of inspired oxygen ratio, suggesting partial reversal of cytokine-driven organ dysfunction, though the survival benefit did not reach statistical significance (adjusted OR 5.97; P =0.117).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.